Nuo Therapeutics, Inc. (AURX): Results of Operations and Financial Condition
Nuo Therapeutics, Inc. (AURX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99 2 ex_1005708.htm EXHIBIT 99 ex_1005708.htm Exhibit 99 8285 El Rio, Suite 190 Houston, TX 77054 Phone 833.298.6633 NUO THERAPEUTICS ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Differentiated Autologous PRP Remains Well-Positioned for Attracti
How this was made
The 30-second read
Why it matters
Traders can update near-term expectations for liquidity and operating trajectory from the loan amendment and Q2 loss improvement, while also reassessing longer-dated demand sensitivity to proposed Medicare PFS and OPPS rules effective January 1, 2027.
Market read
Q2 shows strong revenue growth and improved operating loss, alongside added funding optionality, while the reimbursement catalyst is conditional on proposed 2027 Medicare rules being finalized as proposed.
What to watch
Interest expense is material (net interest expense in Q2), and the reimbursement support is tied to proposed rules that may change before finalization.
Background
This is an SEC Form 8-K (Item 2.02) with a press release covering Nuo Therapeutics’ Q2 2026 financial results and an operational update tied to Medicare reimbursement dynamics for its Aurix autologous PRP therapy.
Ticker impact
Nuo reported Q2 2026 results with revenues up over 150% YoY, plus an amended loan with $675,000 interim funding and $325,000 remaining availability.
Near-term bias positive on liquidity and growth signals, but upside may be capped by continued net losses and dependence on Medicare rule finalization.
Revenue growth and sequential product revenue increases are concrete, and the loan amendment adds funding optionality. However, the reimbursement benefit is conditional on proposed 2027 rules being finalized, and the company still reports a net loss and sizable liabilities.
Market effects
Reimbursement rulemaking for autologous PRP therapies could influence expectations for regenerative wound-care device peers, but this is company-specific framing.
No clear regional market linkage beyond US Medicare reimbursement policy.
Limited, as the catalyst is US Medicare reimbursement for Aurix.
Counterpoint
Revenue growth may reflect low base effects and distribution fee timing, while the company remains loss-making and relies on continued financing.
Key entities
- issuerNuo Therapeutics, Inc.
Commercial-stage medical device company marketing Aurix autologous PRP therapy for chronic wound care.
- productAurix
Biodynamic hematogel system used for autologous PRP therapies in chronic wound care.
- regulatoryMedicare PFS and OPPS reimbursement rules
Proposed rules issued in July for January 1, 2027 effectiveness that Nuo says could support stable or increasing Medicare payments.
- financingLoan agreement amendment
Amended and restated loan with interim funding of $675,000 and $325,000 remaining available under commitments totaling $2 million.
